MedTrace Logo

Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma

NCT00961844 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2021-02-26

No results posted yet for this study

Summary

In this trial the investigators want to combine chemotherapy with immunotherapy by giving the patients Temozolomide, before vaccination. The investigators have also included hTERT and survivin mRNA in the vaccine. Finally, the investigators want to introduce ex vivo T cell expansion after lymphodepletion for the patients who show an immune response.

Conditions

  • Metastatic Malignant Melanoma

Interventions

BIOLOGICAL

Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion

DRUG

Temozolomide

Sponsors & Collaborators

  • Steinar Aamdal

    lead OTHER

Principal Investigators

  • Steinar Aamdal, M.D PhD Prof · Oslo University Hospital - Norwegian Radium Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00961844 on ClinicalTrials.gov